Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing Infection Risk in Patients with Inflammatory Bowel Disease Undergoing Vedolizumab Treatment: A Systematic Review and Meta-Analysis

  • By

  • Lidan Zhang

  • Xiaogang Hao

  • Yidan Cui

  • Wenjian Yan

  • Kun Shang

  • Xin Zhang

  • June 11, 2026

Share

Original Source(s)

Infection risk in inflammatory bowel disease patients treated with vedolizumab: a systematic review and meta-analysis

  • by Lidan Zhang, Xiaogang Hao, Yidan Cui, Wenjian Yan, Kun Shang, Xin Zhang

  • June 11, 2026

Related Content

Association between OLD and IBD: a systematic review and meta-analysis

Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial

Nurr1 deficiency orchestrates a coupled liver–gut pathological axis revealed by multi-omics and deep-learning histopathology